A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (NCT06365853)
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \[PSOC\] or platinum-resistant ovarian cancer \[PROC\]) with high folate receptor alpha (FRΞ±) expression.
Who can join: Review the eligibility criteria below.
Location: University of California Los Angeles /ID# 269339 β Los Angeles, California
Age range: 18 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (41 Sites)
Showing the first 25 of 41 sites.
- University of California Los Angeles /ID# 269339 β Los Angeles, California
- UCSF Medical Center /ID# 280425 β San Francisco, California
- Norton Cancer Institute - St. Matthews /ID# 269070 β Louisville, Kentucky
- Holy Cross Hospital - Silver Spring /ID# 269344 β Silver Spring, Maryland
- Mercy David C. Pratt Cancer Center /ID# 269350 β St Louis, Missouri
- The Center Of Hope /ID# 269348 β Reno, Nevada
- Holy Name Medical Center /ID# 269340 β Teaneck, New Jersey
- New York Oncology Hematology - Albany Cancer Center /ID# 269345 β Albany, New York
- Women'S Cancer Care Associates /ID# 269980 β Albany, New York
- Duke Cancer Institute /ID# 269342 β Durham, North Carolina
- Summa Health /ID# 269349 β Akron, Ohio
- University of Texas - Southwestern Medical Center /ID# 269341 β Dallas, Texas
- Memorial Hermann Southeast Hospital /ID# 269347 β Houston, Texas
- Blacktown Hospital /ID# 269305 β Blacktown, New South Wales
- Newcastle Private Hosptial /ID# 269306 β Lambton Heights, New South Wales
- Monash Health - Monash Medical Centre - Clayton /ID# 269304 β Clayton, Victoria
- Universitair Ziekenhuis Antwerpen /ID# 269310 β Edegem, Antwerpen
- OLV Ziekenhuis Aalst /ID# 269311 β Aalst, Oost-Vlaanderen
- AZ Sint-Lucas /ID# 269307 β Ghent, Oost-Vlaanderen
- UZ Gent /ID# 269309 β Ghent, Oost-Vlaanderen
- Universitair Ziekenhuis Leuven /ID# 269308 β Leuven, Vlaams-Brabant
- CHU de Liege /ID# 269312 β LiΓ¨ge,
- Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 268862 β Montreal, Quebec
- Centre Hospitalier de l'Universite de Montreal /ID# 269314 β Montreal, Quebec
- McGill University Health Centre - Glen Site /ID# 269313 β Montreal, Quebec
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Recurrent Ovarian Cancer
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. β Durham, North Carolina
- Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer β Toronto, Ontario
- Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients β San Francisco, California
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers β Birmingham, Alabama
- CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer β Pittsburgh, Pennsylvania
Explore by condition: All Recurrent Ovarian Cancer clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.